



Press Release

Wednesday, February 24, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE : 532531

NSE : STAR

Audited Financial Results for the Year ended 31 December 2009

Delivers Strong growth in Revenue and Profitability

Snapshot

Consolidated	Stand-Alone
Revenue at Rs.1,328 Crores up by 23% (Rs.1080 Crores in 2008).	Revenue at Rs.769 Crores up by 30% (Rs.593 Crores in 2008).
Operating EBITDA at Rs.211 Crores up by 62% Rs.211 Crores (Rs.130 Crores in 2008).	Operating EBITDA at Rs.140 Crores up by 45% Rs.140 Crores (Rs.97 Crores in 2008).
PBT at Rs.143 Crores up by 24% (Rs 115 Crores in 2008)	PBT at Rs.117 Crores up by 100+% (Rs. 5 Crores in 2008)

Highlights

- Consolidated Revenue from continuing Operations up by 33%
- Dividend of Rs.1.50 Per equity share
- Record ANDA filings – 51 filings against a guidance of 40
- Collaboration with Pfizer on Specialty sterile injectables announced

- Launch of 'Ray of Life' – Critical care division in the Branded generics space in India.
- Successful completion of reorganization resulting in well articulated business divisions.
- Buyback of FCCBs worth face value of USD 26 Million during the year.
- Commenced commercial supplies of Oseltamivir Capsules For Influenza-A(H1N1) Virus (Swine Flu)".
- Continued regulatory approvals for all manufacturing sites.

The Board approved issue of 25,60,000 shares on conversion of warrants to the Promoters. Post conversion, Promoter holdings is at 30.13% against existing 25.68%.

Strides Arcolab's Vice Chairman & Group CEO Mr. Arun Kumar commented "The year 2009 has been a year of strong performance. We delivered a significant increase in our R&D filings and Business development activities including a transformational deal with Pfizer for Specialty Sterile injectables.. I am extremely delighted that we are delivering value to our stake-holders.

Performance highlights for the year 2009 is attached as a presentation.

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries, including its joint venture with Aspen in India and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

Mr. T.S. Rangan - Group CFO Tel: +91 80 6658 0115	Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 9880376648 Email: maheshn@corvoshandwick.co.in
Mr.N.Kannan, Company Secretary (Investors) Tel : +91 80 6658 0751	Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: +91 9916728393 Email: kasturi@corvoshandwick.co.in
Melissa Arulappan (Media) Tel: +91 98450 22389	

